Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 2446413

[2 years' experiences with cavernosal autoinjection therapy].

C G Stief·W F Thon·W Scherb·H Gall·W Bähren
View original source ↗Export metadata ↓

Abstract

Between February 1985 and January 1987, 186 patients with erectile dysfunction were selected for cavernosal autoinjection therapy (CAT). After more than 4800 protocolled autoinjections and 10-230 CAT/pt., no cavernous fibrosis, penile deviation or cavernitis occurred. The only serious side effects were prolonged erections in about 10% during diagnostic and less than 1% during therapeutic use. These prolonged erections could be easily treated by puncture and aspiration of corpora cavernosa or intracavernosal injection of Metaraminol.

Explore related subjects

Drug Therapy, CombinationErectile DysfunctionHumansInjectionsMaleMetaraminolPapaverinePenile ErectionPenisPhentolamineEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C G Stief, W F Thon, W Scherb, H Gall, W Bähren. 1987. [2 years' experiences with cavernosal autoinjection therapy].. https://pubmed.ncbi.nlm.nih.gov/2446413/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].

According to the NIH scheme, the "evidence based medicine" standard in the treatment of severe proliferative lupus-nephritis is cyclophosphamide in combination with steroids. Undesired effects, therapy resistance, and deficient long-term effects underscore the necessity for the development of alternative therapies for the treatment of organ involvement. Mycophenolate mofetil (MMF) possesses the potential to decisively improve the therapeutic possibilities for systemic lupus erythematosus (SLE). On the basis of the available data, MMF represents an alternative to the current standard therapies for severe lupus-nephritises and shows less toxicity. MMF is also effective in patients with other manifestations refractory to conventional therapy. Questions remain unanswered on the optimal dosage and possible reduction in cases of remission. In addition, the duration of maintenance therapy is unclear. Therefore, large, prospective, randomized clinical studies in the treatment of lupus-nephritis with a sufficiently long follow-up phase are underway.

Drug Therapy, Combination↗